STALICLA SA Secures $17.4 Million in Series B Funding to Revolutionize Neuro Precision Medicine

STALICLA SA, the Swiss clinical-stage biopharmaceutical company at the forefront of Neuro Precision Medicine for neurodevelopmental and neuropsychiatric disorders, has successfully raised $17,400,000 in funding. The company's innovative approach utilizes cutting-edge technology platforms and clinical trials to revolutionize treatments for Autism Spectrum Disorder (ASD) and Substance Use Disorder (SUD). With a focus on identifying patient subgroups and developing tailored precision treatments, STALICLA is pushing boundaries in brain disease research. This latest funding round will support the company in advancing Phase 2 trials for STP1 in ASD and Phase 3 trials for STP7 in SUD in collaboration with the National Institute of Drug Abuse (NIDA). STALICLA's commitment to driving advancements in both neurodevelopmental and substance abuse fields underscores its dedication to improving patient outcomes and reshaping the landscape of brain disease therapies. For more information on STALICLA's transformative work, visit their website at https://stalicla.com.